Rabab Nasrallah

Partner at Earlybird Venture Capital

Speaker

Rabab Nasrallah is Partner at Earlybird Health and brings a therapeutics and platform-led investment perspective with a strong record of execution, having closed several transactions across Earlybird Health I & II.

Since joining Earlybird in 2020, she has executed deals end-to-end and co-developed the firm's biotech investment strategy with clear value-inflection plans and capital discipline. Rabab maintains a deep network across VC and strategic pharma in Europe and the US, using those relationships to build high-quality syndicates and partnerships to support companies with breakthrough technologies.

She serves on the boards of HAYA Therapeutics, Greywolf Therapeutics, and Portal Biotech, and is a board observer at GEMMABio, Priothera, ImCheck Therapeutics, and Prothea Technologies. Beyond investing, she engages with stakeholders to understand how platform scale in biotech can be realized and valued alongside individual assets.